Company to host conference call and webinar today at 8:00 a.m. EDT REDWOOD CITY, Calif., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (JSPR) (Jasper), a clinical stage biotechnology ...
(n=6) enrolled in the BEACON study achieved a complete response at 12 weeks with a mean UAS7 reduction of 31 points 75% of ...
Jasper anticipates reporting preliminary data from the SPOTLIGHT study in the second half of 2024. Announced expansion of the Company’s mast cell portfolio with a new briquilimab development program ...
REDWOOD CITY, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody ...
Jasper Therapeutics, Inc. announced promising preliminary results from its BEACON Phase 1b/2a study of briquilimab, an experimental therapy targeting mast cell-driven diseases like chronic spontaneous ...
REDWOOD CITY, Calif., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel ...
(n=6) enrolled in the BEACON study achieved a complete response at 12 weeks with a mean UAS7 reduction of 31 points ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback